Skip to main content
Journal cover image

Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome.

Publication ,  Journal Article
Bainbridge, MN; Mazumder, A; Ogasawara, D; Abou Jamra, R; Bernard, G; Bertini, E; Burglen, L; Cope, H; Crawford, A; Derksen, A; Dure, L ...
Published in: Brain
October 21, 2022

The endocannabinoid system is a highly conserved and ubiquitous signalling pathway with broad-ranging effects. Despite critical pathway functions, gene variants have not previously been conclusively linked to human disease. We identified nine children from eight families with heterozygous, de novo truncating variants in the last exon of DAGLA with a neuro-ocular phenotype characterized by developmental delay, ataxia and complex oculomotor abnormality. All children displayed paroxysms of nystagmus or eye deviation accompanied by compensatory head posture and worsened incoordination most frequently after waking. RNA sequencing showed clear expression of the truncated transcript and no differences were found between mutant and wild-type DAGLA activity. Immunofluorescence staining of patient-derived fibroblasts and HEK cells expressing the mutant protein showed distinct perinuclear aggregation not detected in control samples. This report establishes truncating variants in the last DAGLA exon as the cause of a unique paediatric syndrome. Because enzymatic activity was preserved, the observed mislocalization of the truncated protein may account for the observed phenotype. Potential mechanisms include DAGLA haploinsufficiency at the plasma membrane or dominant negative effect. To our knowledge, this is the first report directly linking an endocannabinoid system component with human genetic disease and sets the stage for potential future therapeutic avenues.

Duke Scholars

Published In

Brain

DOI

EISSN

1460-2156

Publication Date

October 21, 2022

Volume

145

Issue

10

Start / End Page

3383 / 3390

Location

England

Related Subject Headings

  • Syndrome
  • Phenotype
  • Neurology & Neurosurgery
  • Nervous System Diseases
  • Mutant Proteins
  • Humans
  • Heterozygote
  • Endocannabinoids
  • Child
  • 52 Psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bainbridge, M. N., Mazumder, A., Ogasawara, D., Abou Jamra, R., Bernard, G., Bertini, E., … Friedman, J. (2022). Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain, 145(10), 3383–3390. https://doi.org/10.1093/brain/awac223
Bainbridge, Matthew N., Aloran Mazumder, Daisuke Ogasawara, Rami Abou Jamra, Geneviève Bernard, Enrico Bertini, Lydie Burglen, et al. “Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome.Brain 145, no. 10 (October 21, 2022): 3383–90. https://doi.org/10.1093/brain/awac223.
Bainbridge MN, Mazumder A, Ogasawara D, Abou Jamra R, Bernard G, Bertini E, et al. Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain. 2022 Oct 21;145(10):3383–90.
Bainbridge, Matthew N., et al. “Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome.Brain, vol. 145, no. 10, Oct. 2022, pp. 3383–90. Pubmed, doi:10.1093/brain/awac223.
Bainbridge MN, Mazumder A, Ogasawara D, Abou Jamra R, Bernard G, Bertini E, Burglen L, Cope H, Crawford A, Derksen A, Dure L, Gantz E, Koch-Hogrebe M, Hurst ACE, Mahida S, Marshall P, Micalizzi A, Novelli A, Peng H, Rady Children’s Institute for Genomic Medicine, Rodriguez D, Robbins SL, Rutledge SL, Scalise R, Schließke S, Shashi V, Srivastava S, Thiffault I, Topol S, Undiagnosed Disease Network, Qebibo L, Wieczorek D, Cravatt B, Haricharan S, Torkamani A, Friedman J. Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. Brain. 2022 Oct 21;145(10):3383–3390.
Journal cover image

Published In

Brain

DOI

EISSN

1460-2156

Publication Date

October 21, 2022

Volume

145

Issue

10

Start / End Page

3383 / 3390

Location

England

Related Subject Headings

  • Syndrome
  • Phenotype
  • Neurology & Neurosurgery
  • Nervous System Diseases
  • Mutant Proteins
  • Humans
  • Heterozygote
  • Endocannabinoids
  • Child
  • 52 Psychology